Skip to main content

Advertisement

Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: The expansion of targetable biomarkers for CAR T cell therapy

Fig. 4

Biomarker targets for hematological malignancies. The endogenous function of each of a CD5, b BCMA, c CD33, d CD38, e CD70, and f IL13Rα2 are shown. These targets are all being utilized to treat hematological malignancies in clinical trials. They are not cancer-specific and do have expression on normal cells, but have an elevation within cancer that is being used for targeting

Back to article page